Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Perifosine plus bortezomib + dexamethasone in relapsed or relapsed/refractory multiple myeloma
2010-018893-19Phase 3Terminated
- Sponsor
- COSCIENS Biopharma Inc.
- Start
- Nov 2010
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in multiple myeloma (MM) comparing Perifosine + bortezomib + dexamethasone with Placebo + bortezomib + dexamethasone (2 arms). Primary endpoint: Progression-free survival. Started Nov 2010; status: terminated.
02
Drugs
perifosine
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on 2010-018893-19.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2010-018893-19.